Special Concept Development

Sam Chun Dang Pharm (SCD), which frequently utilizes the English expansion "Special Concept Development," is a leading South Korean pharmaceutical company established in 1943. The company is a dominant player in the ophthalmic sector, offering an extensive portfolio of eye drops and specialized treatments, while aggressively expanding into the global biosimilar and novel drug delivery markets. Its lead pipeline candidate, SCD411, is a biosimilar of Eylea (aflibercept) that has successfully completed Phase 3 clinical trials and is currently undergoing regulatory filings in major global markets. Furthermore, SCD is leveraging its proprietary S-PASS platform, a technology designed to convert injectable biologics into oral formulations, with a focus on developing oral versions of insulin and GLP-1 agonists for metabolic diseases.